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Introduction
Inflammatory bowel diseases (IBDs) are characterized by
inflammation and intestinal damage. The S100 proteins
S100A8/A9 and S100A12 have been suggested to be
useful for assessing disease activity and monitor treat-
ment efficacy. S100A8/A9 is produced by granulocytes,
monocytes and macrophages whereas S100A12 expres-
sion is restricted to granulocytes and may thus be more
specific.
Aim
To develop an ELISA for fecal S100A12 and investigate
its utility for the clinical investigation of patients with
UC and CD.
Patients and methods
The ELISA (Inflamark™, Cisbio bioassays) is based on 2
monoclonal antibodies raised against recombinant
human S100A12. After stool extraction, S100A12 was
measured in UC (n=30), CD (n=30) and healthy (n=30)
subjects. Fecal S100A12 was correlated with the endo-
scopic Mayo score in subjects with UC and data were
compared to fecal S100A8/A9.
Results
Western blotting showed that the two antibodies
selected for the ELISA recognized both recombinant
and purified native human S100A12 and did not cross-
react with S100A8/A9. Intra and inter assay precision
errors were below 10%. Fecal S100A12 levels were
significantly higher in UC (median: 167 μg/g stool,
p<0.0001) and CD (median 14 μg/g stool, p<0.0001)
patients than in healthy controls (median: 0), with a cor-
responding area under the ROC of 0.83 (p <0.0001) and
0.71 (p<.0001), in UC and CD, respectively. In patients
with UC, fecal S100A12 correlated with the endoscopic
Mayo score (r=0.48, p=0.0067) and levels were on aver-
age 24 fold higher in subjects presenting with active
( n = 1 6 ,M a y os c o r e2 - 3 )t h a ni np a t i e n t sw i t hi n a c t i v e
(n=14, Mayo score 0-1) disease. The difference between
active and non-active UC patients was lower (5.2 fold)
for S100A8/9 than for S100A12 and did not reach statis-
tical significance (p=0.067).
Conclusions
The new ELISA for fecal S100A12 is precise and could
detect increased inflammatory activity in patients with
UC and CD. Measurements of fecal S100A12 should be
useful for the non-invasive assessment of intestinal
damage in patients with IBDs.
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